Fate can be altered
Discovering and developing first-in-class small molecule drugs for improved treatment of diseases with significant clinical need.
More info More info
Vision
We aim to become globally recognized for developing breakthrough therapies to treat incurable diseases. Through intelligent identification and validation of protein and mRNA targets that drive disease progression and modulating their activity with small molecules, we strive to change the fate of patients by stopping the progression and reversing the effects of diseases with unmet medical need.
More info More info
Pipeline
Molecure’s exceptional in-house medicinal chemistry, biology and discovery capabilities allied to novel target biology gained from leading universities worldwide has enabled us to create a broad pipeline of drug candidates targeting unique and unexplored protein targets, as well as a cutting-edge small molecule mRNA targeting discovery platform.
Discover our pipeline Discover our pipelineNews
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure has released its financial report for the first half of 2024. The company continues to develop innovative therapies in the fight against oncological and inflammatory-fibrotic diseases
Invitation to investor meeting 1st October 2024, 2:00 pm (CET)
Dr Piotr Iwanowski appointed as Chief Medical Officer and Board Member of Molecure
Join us
People are the foundation of Molecure’s success. Our scientists are the creators of the best ideas for the multiple new small molecule medicines that are invented in the laboratories. The Molecure team works together to discover the therapies needed to improve the treatment of previously incurable diseases.
It is this unified goal that guides us every day. We are inspired by science, we discover and create. For us, work is a passion.